Polivy Market 2026 strengthening lymphoma treatment innovation

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Polivy Market Evolve From 2026 To 2030?

Historically, growth was fueled by the growing prevalence of diffuse large b-cell lymphoma, significant strides in monoclonal antibody development, the increasing number of oncology treatment centers, a rise in the use of targeted cancer therapies, and enhanced diagnostic abilities.

The projected growth in the upcoming period can be attributed to the rising demand for customized oncology medications, increasing financial commitments towards antibody-drug conjugate research pipelines, the broadening application of initial combination therapies, an intensified focus on lymphomas that resist treatment, and the increasing regulatory approvals for specific biological drugs.

Major developments expected during the forecast period include a growing acceptance of antibody-drug conjugates, their increased utilization in therapies targeting lymphoma, a greater integration with combination chemotherapy protocols, the expansion of precise oncology treatments, and a heightened emphasis on medications designed to target CD79b.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20183&type=smp

What Major Drivers Are Influencing Demand In The Polivy Market?

The growth of the Polivy market is anticipated to be propelled by the increasing occurrence of diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL), recognized as the most common form of non-Hodgkin lymphoma (NHL), is an aggressive blood cancer that develops from B-lymphocytes, which are essential white blood cells in the immune system responsible for producing antibodies to fight infections. The escalating incidence of diffuse large B-cell lymphoma can be attributed to several elements, including an aging population, a rise in immunosuppression caused by conditions such as HIV/AIDS and organ transplants, and environmental factors contributing to the disease’s development. Polivy is utilized in conjunction with chemotherapy to address relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have previously undergone treatments. For instance, according to a report from the Royal College of Pathologists, a UK-based professional membership organization, published in July 2024, approximately 5,500 individuals in the UK are diagnosed with diffuse large B-cell lymphoma (DLBCL) each year, with about 30% of these patients experiencing refractory disease or relapse shortly after their initial treatment. Therefore, the rising incidence of diffuse large B-cell lymphoma is a primary driver for the polivy market’s expansion.

Which Segment Areas Are Covered In The Polivy Market Analysis?

The polivy market covered in this report is segmented –

1) By Indication: Previously Untreated Diffuse Large B-Cell Lymphoma, Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

2) By Dosage Form: Injectable Solution

3) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies

What Key Developments And Trends Are Impacting The Polivy Market?

Leading companies in the polivy market are concentrating on developing novel treatment approaches, such as initial antibody-drug conjugate (ADC) combinations, to more effectively target aggressive B-cell lymphomas and enhance patient outcomes. A first-line ADC combination integrates a monoclonal antibody that selectively binds to tumor-specific proteins with a cytotoxic payload, enabling highly precise therapy, unlike conventional chemotherapy, which affects both cancerous and healthy cells. For instance, in April 2023, Genentech, a U.S.-based biotechnology company, received FDA approval for Polivy (polatuzumab vedotin-piiq) when combined with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy is a pioneering anti-CD79b ADC developed using Seagen’s linker-payload technology: the antibody targets the CD79b protein on B-cells, the conjugated payload (vedotin) is a potent microtubule-disrupting agent, and upon binding, the drug is internalized into the cancer cell where the cytotoxic agent is released to induce cell death. Its distinct attributes include high specificity for malignant B-cells, an improved safety profile compared to systemic chemotherapy, and a demonstrated 27% reduction in the risk of progression or death versus standard R-CHOP in the pivotal POLARIX study. This combination is now poised to revolutionize first-line treatment in DLBCL, potentially lowering relapse rates and easing the long-term burden on patients.

Which Global Companies Are Actively Competing In The Polivy Market?

Major companies operating in the polivy market are F. Hoffmann-La Roche Ltd (Genentech Inc.)

Read the full polivy market report here:

https://www.thebusinessresearchcompany.com/report/polivy-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Polivy Market?

North America was the largest region in the polivy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polivy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Polivy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20183&type=smp

Browse Through More Reports Similar to the Global Polivy Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795